The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial
Abstract
CONTEXT: Men with overactive bladder and other lower urinary tract symptoms may not respond to monotherapy with antimuscarinic agents or alpha-receptor antagonists. OBJECTIVE: To evaluate the efficacy and safety of tolterodine extended release (ER), tamsulosin, or both in men who met research criteria for both overactive bladder and benign prostatic hyperplasia. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted at 95 urology clinics in the United States involving men 40 years or older who had a total International Prostate Symptom Score of 12 or higher and, an International Prostate Symptom Score quality-of-life (QOL) item score of 3 or higher, a self-rated bladder condition of at least moderate bother, and a bladder diary documenting micturition frequency (>or=8 micturitions per 24 hours) and urgency (>or=3 episodes per 24 hours), with or without urgency urinary incontinence. Patients were recruited between November 2004 and February 2006, and the study was completed May 2006. INTERVENTIONS: Patients were randomly assigned to receive placebo (n = 222), 4 mg of tolterodine ER (n = 217), 0.4 mg of tamsulosin (n = 215), or both tolterodine ER plus tamsulosin (n = 225) for 12 weeks. MAIN OUTCOME MEASURES: Patient perception of treatment benefit, bladder diary variables, International Prostate Symptom Scores, and safety and tolerability were assessed. RESULTS: A total of 172 men (80%) receiving tolterodine ER plus tamsulosin reported treatment benefit by week 12 compared with 132 patients (62%) receiving placebo (P<.001), 146 (71%) receiving tamsulosin (P=.06 vs placebo), or 135 (65%) receiving tolterodine ER (P=.48 vs placebo). Patients receiving tolterodine ER plus tamsulosin compared with placebo experienced significant reductions in urgency urinary incontinence (-0.88 vs -0.31, P=.005), urgency episodes without incontinence (-3.33 vs -2.54, P=.03), micturitions per 24 hours (-2.54 vs -1.41, P<.001), and micturitions per night (-0.59 vs -0.39, P.02). Patients receiving tolterodine ER plus tamsulosin demonstrated significant improvements on the total International Prostate Symptom Score (-8.02 vs placebo, -6.19, P=.003) and QOL item (-1.61 vs -1.17, P=.003). All interventions were well tolerated. The incidence of acute urinary retention requiring catheterization was low (tolterodine ER plus tamsulosin, 0.4%; tolterodine ER, 0.5%; tamsulosin, 0%; and placebo, 0%). CONCLUSIONS: These results suggest that treatment with tolterodine ER plus tamsulosin for 12 weeks provides benefit for men with moderate to severe lower urinary tract symptoms including overactive bladder. Clinical Trials Registration clinicaltrials.gov Identifier: NCT00147654.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., Van Kerrebroeck, P., Victor, A., & Wein, A. (2003) · Urology · doi:10.1016/s0090-4295(02)02243-4 · Cited by 3,220
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030656 · Cited by 2,043
Self-citationThe American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O'leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & Measurement Committee of the American Urological Association (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.071 · Cited by 1,940
Milsom, I., Abrams, P., Cardozo, L., Roberts, R. G., Thüroff, J., & Wein, A. J. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02228.x · Cited by 1,752
Methods to Explain the Clinical Significance of Health Status Measures
Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., & Norman, G. R. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.4.371 · Cited by 1,500
Defining clinically meaningful change in health-related quality of life
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00044-1 · Cited by 1,332
Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin.
Stamler, J. S., Jaraki, O., Osborne, J., Simon, D. I., Keaney, J., Vita, J., Singel, D., Valeri, C. R., & Loscalzo, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7674 · Cited by 1,238
The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350801 · Cited by 792
Cited by
Muscarinic receptor antagonists for overactive bladder
Abrams, P., & Andersson, K. (2007) · BJU International · doi:10.1111/j.1464-410x.2007.07205.x · Cited by 405
Drug-Induced Urinary Retention: Incidence, Management and Prevention
Verhamme, K. M. C., Sturkenboom, M. C. J. M., Stricker, B. H. C., & Bosch, R. (2008) · Drug Safety · doi:10.2165/00002018-200831050-00002 · Cited by 264
Sexton, C. C., Notte, S. M., Maroulis, C., Dmochowski, R. R., Cardozo, L., Subramanian, D., & Coyne, K. S. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02626.x · Cited by 254
Metadata
- Authors
- Kaplan, S. A., Roehrborn, C. G., Rovner, E. S., Carlsson, M., Bavendam, T., & Guan, Z.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-11-15
- Volume
- 296
- Issue
- 19
- Pages
- 2319
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2134121470
- Cited by
- 516
- References
- 28
- FWCI
- 37.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1001/jama.296.19.2319
- The paper
- Kaplan, S. A., Roehrborn, C. G., Rovner, E. S., Carlsson, M., Bavendam, T., & Guan, Z. (2006). Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder: A Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.296.19.2319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.